Non-falciparum malaria infection and IgG seroprevalence among children under 15 years in Nigeria, 2018.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
13 03 2023
Historique:
received: 12 08 2022
accepted: 27 02 2023
entrez: 14 3 2023
pubmed: 15 3 2023
medline: 16 3 2023
Statut: epublish

Résumé

Plasmodium falciparum (Pf) is the dominant malaria parasite in Nigeria though P. vivax (Pv), P. ovale (Po), and P. malariae (Pm) are also endemic. Blood samples (n = 31,234) were collected from children aged 0-14 years during a 2018 nationwide HIV survey and assayed for Plasmodium antigenemia, Plasmodium DNA, and IgG against Plasmodium MSP1-19 antigens. Of all children, 6.6% were estimated to have Pm infection and 1.4% Po infection with no Pv infections detected. The highest household wealth quintile was strongly protective against infection with Pm (aOR: 0.11, 95% CI: 0.05-0.22) or Po (aOR= 0.01, 0.00-0.10). Overall Pm seroprevalence was 34.2% (95% CI: 33.3-35.2) with lower estimates for Po (12.1%, 11.6-12.5) and Pv (6.3%, 6.0-6.7). Pm seropositivity was detected throughout the country with several local government areas showing >50% seroprevalence. Serological and DNA indicators show widespread exposure of Nigerian children to Pm with lower rates to Po and Pv.

Identifiants

pubmed: 36914649
doi: 10.1038/s41467-023-37010-0
pii: 10.1038/s41467-023-37010-0
pmc: PMC10011577
doi:

Substances chimiques

Antigens, Protozoan 0
Immunoglobulin G 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1360

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

Références

PLoS Med. 2011 Jan 25;8(1):e1000400
pubmed: 21311581
Int J Parasitol. 2022 Jan;52(1):23-33
pubmed: 34390743
Lancet. 2014 Feb 22;383(9918):723-35
pubmed: 23953767
Malar J. 2020 Jun 26;19(1):229
pubmed: 32590997
Malar J. 2018 Jul 6;17(1):252
pubmed: 29976204
Am J Trop Med Hyg. 2020 Dec;103(6):2208-2216
pubmed: 33124531
Malar J. 2016 Jan 29;15:53
pubmed: 26823277
Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5108-13
pubmed: 15792998
MMWR Morb Mortal Wkly Rep. 2019 Nov 22;68(46):1062-1068
pubmed: 31751320
Trends Parasitol. 2018 May;34(5):420-429
pubmed: 29530446
J Parasitol. 1999 Feb;85(1):12-8
pubmed: 10207356
BMC Infect Dis. 2014 Mar 26;14:168
pubmed: 24669881
Malar J. 2016 Apr 18;15:219
pubmed: 27091046
Malar J. 2020 Oct 30;19(1):384
pubmed: 33126886
Emerg Infect Dis. 2022 Oct;28(10):2043-2050
pubmed: 36148905
Am J Trop Med Hyg. 1999 Aug;61(2):339-43
pubmed: 10463691
Malar J. 2018 Nov 28;17(1):439
pubmed: 30486887
Malar J. 2021 Sep 8;20(1):364
pubmed: 34493280
Malar J. 2018 Nov 9;17(1):417
pubmed: 30413163
Infect Drug Resist. 2019 Jul 05;12:1941-1949
pubmed: 31308714
PLoS One. 2017 Jun 22;12(6):e0179178
pubmed: 28640824
Emerg Infect Dis. 2022 Mar;28(3):608-616
pubmed: 35201739
Am J Epidemiol. 2018 Apr 1;187(4):864-870
pubmed: 29020135
Malar J. 2019 Jun 27;18(1):218
pubmed: 31248414
Nat Commun. 2021 Jul 7;12(1):4169
pubmed: 34234124
Am J Trop Med Hyg. 1980 Sep;29(5):725-37
pubmed: 6969036
Int J Health Policy Manag. 2018 May 07;7(9):859-866
pubmed: 30316234
Biometrics. 1998 Jun;54(2):638-45
pubmed: 9629647
Infect Dis Poverty. 2021 Aug 23;10(1):113
pubmed: 34425898
J Infect Dis. 2019 Jan 9;219(3):437-447
pubmed: 30202972
Trans R Soc Trop Med Hyg. 1979;73(2):216-8
pubmed: 382466
PLoS One. 2012;7(9):e45542
pubmed: 23029082
Malar J. 2014 Jun 18;13:240
pubmed: 24946685
PLoS One. 2013;8(2):e56677
pubmed: 23437209
Nat Commun. 2022 Feb 21;13(1):976
pubmed: 35190534
Malar J. 2019 Mar 25;18(1):98
pubmed: 30909912
PLoS Negl Trop Dis. 2019 Jan 31;13(1):e0007140
pubmed: 30703083
Malar J. 2015 Nov 04;14:436
pubmed: 26537125
Sci Rep. 2019 Nov 25;9(1):17500
pubmed: 31767899
Malar J. 2014 Nov 26;13:463
pubmed: 25428624
West Afr J Med. 2003 Sep;22(3):250-2
pubmed: 14696952
PLoS Negl Trop Dis. 2019 May 28;13(5):e0007414
pubmed: 31136585
Trends Parasitol. 2007 Dec;23(12):575-82
pubmed: 17988945
Cochrane Database Syst Rev. 2013 Oct 25;(10):CD008492
pubmed: 24163021
Open Forum Infect Dis. 2022 Jan 19;9(3):ofac025
pubmed: 35187194
Acta Parasitol. 2021 Sep;66(3):915-924
pubmed: 33710479
Int J Environ Res Public Health. 2020 Oct 30;17(21):
pubmed: 33142978
Sci Rep. 2020 Jan 24;10(1):1135
pubmed: 31980693
Malar J. 2017 May 6;16(1):189
pubmed: 28477621
Sci Rep. 2021 Jun 24;11(1):13248
pubmed: 34168264

Auteurs

Camelia Herman (C)

Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, 30029, USA.
BeVera Solutions, Atlanta, GA, 30341, USA.

Colleen M Leonard (CM)

Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, 30029, USA.
Oak Ridge Institute for Science and Education, US. Department of Energy, Oak Ridge, TN, 37831, USA.

Perpetua Uhomoibhi (P)

National Malaria Elimination Programme, Federal Ministry of Health, Abuja, Nigeria.

Mark Maire (M)

U.S. President's Malaria Initiative, Malaria Branch, Division of Parasitic Diseases and Malaria, U.S. Centers for Disease Control and Prevention, Abuja, Nigeria.

Delynn Moss (D)

Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Uwem Inyang (U)

U.S. President's Malaria Initiative, United States Agency for International Development (USAID), Abuja, Nigeria.

Ado Abubakar (A)

Institute of Human Virology (IHVN), Abuja, Nigeria.

Abiodun Ogunniyi (A)

Nigeria Centre for Disease Control (NCDC), Abuja, Nigeria.

Nwando Mba (N)

Nigeria Centre for Disease Control (NCDC), Abuja, Nigeria.

Stacie M Greby (SM)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria.

McPaul I Okoye (MI)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria.

Nnaemeka C Iriemenam (NC)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria.

Ibrahim Maikore (I)

World Health Organization, Nigeria Country Office, Abuja, Nigeria.

Laura Steinhardt (L)

Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, 30029, USA.

Eric Rogier (E)

Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, 30029, USA. erogier@cdc.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH